Page 1687 - Williams Hematology ( PDFDrive )

1662 Part XI: Malignant Lymphoid Diseases <CN>: <ct> PB

for international blood and marrow transplant research. Biol Blood Marrow Transplant 84. Wang ML, Hagemeister F, Westin JR, et al: Ibrutinib and rituximab are an efficacious
19:625, 2013. and safe combination in relapsed mantle cell lymphoma: Preliminary results from a
67. Zoellner A, Fritsch S, Prevalsek D, et al: Sequential therapy combining clofarabine and phase II. (ASH Annual Meeting Abstracts) Blood 124:627, 2014.
HLA-haploidentical hematopoietic stem cell transplantation in the treatment of refrac- 85. Kahl BS, Spurgeon SE, Furman RR, et al: A phase 1 study of the PI3Kδ inhibitor idelalisib in
tory and advanced lymphoma: Feasibility, toxicity and early outcome. (ASH Annual patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 123:3398, 2014.
Meeting Abstracts) Blood 122:4544, 2013. 86. Davids MS, Seymour JF, Gerecitano JF, et al: The single-agent Bcl-2 inhibitor ABT-
68. Wang M, Oki Y, Pro B, et al: Phase II study of yttrium-90-ibritumomab tiuxetan in 199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma
patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:5213, 2009. (NHL): Responses observed in all mantle cell lymphoma (MCL) patients. (ASH Annual
69. Ferrero S, Pastore A, Forstpointner R, et al: Radioimmunotherapy in relapsed/refrac- Meeting Abstracts) Blood 122:1789, 2013.
tory mantle cell lymphoma patients: Final results of a European MCL Network phase II 87. Furtado M, Johnson R, Kruger A, et al: Addition of bortezomib to standard dose chop
trial. (ASH Annual Meeting Abstracts) Blood 122:4384, 2013. chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J
70. Goy A, Bernstein SH, Kahl BS, et al: Bortezomib in patients with relapsed or refractory Haematol 168:55, 2015.
mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PIN- 88. Kouroukis CT, Fernandez LA, Crump M, et al: A phase II study of bortezomib and
NACLE study. Ann Oncol 20:520, 2009. gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of
71. Baiocchi RA, Alinari L, Lustberg ME, et al: Phase 2 trial of rituximab and bortezomib Canada Clinical Trials Group (IND 172). Leuk Lymphoma 52:394, 2011.
in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 89. Weigert O, Weidmann E, Mueck R, et al A novel regimen combining high dose cytara-
117:2442, 2011. bine and bortezomib has activity in multiply relapsed and refractory mantle cell lym-
72. Lamm W, Kaufmann H, Raderer M, et al: Bortezomib combined with rituximab and phoma-long-term results of a multicenter observation study. Leuk Lymphoma 50:716,
dexamethasone is an active regimen for patients with relapsed and chemotherapy-re- 2009.
fractory mantle cell lymphoma. Haematologica 96:1008, 2011. 90. Friedberg JW, Vose JM, Kelly JL, et al: The combination of bendamustine, bortezomib,
73. Kaufmann H, Raderer M, Wöhrer S, et al: Antitumor activity of rituximab plus thalido- and rituximab for patients with relapsed/refractory indolent and mantle cell non
mide in patients with relapsed/refractory mantle cell lymphoma. Blood 104:2269, 2004. -Hodgkin lymphoma. Blood 117:2807, 2011.
74. Zinzani PL, Vose JM, Czuczman MS, et al: Long-term follow-up of lenalidomide in 91. Gerecitano J, Portlock C, Hamlin P, et al: Phase I trial of weekly and twice-weekly borte-
relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann zomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory
Oncol 24:2892, 2013. non-Hodgkin lymphoma. Clin Cancer Res 17:2493, 2011.
75. Goy A, Sinha R, Williams ME, et al: Single-agent lenalidomide in patients with man- 92. Ruan J, Martin P, Furman RR, et al: Bortezomib plus CHOP-rituximab for previously
tle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol
Phase II MCL-001 (EMERGE) study. J Clin Oncol 31:3688, 2013. 29:690, 2011.
76. Wang M, Fayad L, Wagner-Bartak N, Zhang L, et al: Lenalidomide in combination with 93. Zaja F, Ferrero S, Stelitano C et al:. Rituximab, Lenalidomide, Bendamustine second
rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 line therapy in mantle cell lymphoma: a phase II study of the fondazione Italiana lin-
clinical trial. Lancet Oncol 13:716, 2012. fomi (FIL). Hematol Oncol 33(suppl 1):14, 2015.
77. Trneny M, Lamy T, Walewski J, et al: Phase II randomized, multicenter study of lenalid- 94. Ruan J, Martin P, Coleman M, et al: Durable responses with the metronomic rituximab
omide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma: Results and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide reg-
of the MCL-002 (SPRINT) Study. (ASH Annual Meeting Abstracts) Blood 124:626. imen in elderly patients with recurrent mantle cell lymphoma. Cancer 116:2655, 2010.
78. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI- 95. Hess G, Keller U, Scholz CW, et al: Safety and efficacy of temsirolimus in combination
779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347, 2005. with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma.
79. Ansell SM, Inwards DJ, Rowland KM Jr, et al: Low-dose, single-agent temsirolimus for Leukemia 2015 Mar 13 [Epub ahead of print].
relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment 96. Lin TS, Blum KA, Fischer DB, et al: Flavopiridol, fludarabine, and rituximab in mantle
Group. Cancer 113:508, 2008. cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 28:418,
80. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus com- 2010.
pared with investigator’s choice therapy for the treatment of relapsed or refractory man- 97. Robak T, Huang H, Jin J, et al: Bortezomib-based therapy for newly diagnosed mantle-
tle cell lymphoma. J Clin Oncol 27(23):3822–3829, 2009. cell lymphoma. N Engl J Med 372:944, 2015.
81. Ansell SM, Tang H, Kurtin PJ, et al: Temsirolimus and rituximab in patients with 98. Houot R, Le Gouill S, Ojeda Uribe M, et al: Combination of rituximab, bortezomib,
relapsed or refractory mantle cell lymphoma: A phase 2 study. Lancet Oncol 12:361, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for
2011. elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
82. Renner C, Zinzani PL, Gressin R, et al: A multicenter phase II trial (SAKK 36/06) of Ann Oncol 23:1555, 2012.
single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell 99. Herrmann A, Hoster E, Zwingers T, et al: Improvement of overall survival in advanced
lymphoma. Haematologica 97:1085, 2012. stage mantle cell lymphoma. J Clin Oncol 27:511, 2009.
83. Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed or refractory 100. Inwards DJ, Fishkin PA, LaPlant BR, et al: Phase I trial of rituximab, cladribine, and tem-
mantle-cell lymphoma. N Engl J Med 369:507, 2013. sirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol 25:2020, 2014.

Kaushansky_chapter 100_p1653-1662.indd 1662 9/18/15 5:06 PM